NOXXON Announces Three Additional Clinical Centers to Recruit Patients for NOX-A12 Brain Cancer Trial

NOXXON Pharma N.V. announced the collaboration with three additional clinical sites to increase recruitment capacity for the Phase I/II brain cancer study of NOX-A12 plus radiotherapy, as a measure to ensure the timely completion of the study under the current challenging conditions posed by the COVID-19 pandemic.
[NOXXON Pharma N.V.]
Press Release
Bookmark

No account yet? Register

0
Share

Noxxon Announces Successful Completion of Patient Recruitment for Second Dose Cohort In Phase I/II Brain Cancer Study of NOX-A12 Plus Radiotherapy

Biotechnology company NOXXON Pharma N.V. announced that all three patients of the second dose cohort have been enrolled into the brain cancer clinical trial testing CXCL12 inhibitor, NOX-A12, and have already received the planned initial treatment. The Phase I/II clinical study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external beam radiotherapy in newly diagnosed brain cancer patients.
[Noxxon Pharma N.V.]
Press Release
Bookmark

No account yet? Register

0
Share

Megalencephalic Leukoencephalopathy with Subcortical Cysts 1 (MLC1) Promotes Glioblastoma Cell Invasion in the Brain Microenvironment

The authors showed that Mlc1 was expressed in human stem-like glioblastoma (GBM) cells and was linked to the development of primary and recurrent GBM.
[Oncogene]
Lattier, J. M., De, A., Chen, Z., Morales, J. E., Lang, F. F., Huse, J. T., & McCarty, J. H. (2020). Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment. Oncogene, 1–12. https://doi.org/10.1038/s41388-020-01503-9 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy in Brain Cancers

Immunomedics, Inc.announced that Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration of SN-38 for brain metastasis from breast cancer and recurrent glioblastoma, respectively, and produced partial responses in both cohorts of brain cancer patients.
[Immunomedics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Developing Bio-Inspired 3D Models of Brain Cancer to Evaluate Tumor-Homing Neural Stem Cell Therapy

When neural stem cells (NSCs) were implanted 2 mm lateral from the tumor foci, NSCs co-localized with the GBM within seven days. In models of multi-focal disease, NSCs were found to co-localize with multiple tumors, preferentially migrating to tumor foci closest to the site of NSC implantation.
[Tissue Engineering]
Abstract
Bookmark

No account yet? Register

0
Share

Inhibition of Purinergic P2X Receptor 7 (P2X7R) Decreases Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Expression in U251 Glioblastoma Cells

Researchers investigated the potential mechanism linking P2X7R and GM-CSF in the U251 glioblastoma cell line and the therapeutic potential of P2X7R antagonism in this setting.
[Scientific Reports]
Drill, M., Powell, K. L., Kan, L. K., Jones, N. C., O’Brien, T. J., Hamilton, J. A., & Monif, M. (2020). Inhibition of purinergic P2X receptor 7 (P2X7R) decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) expression in U251 glioblastoma cells. Scientific Reports, 10(1), 14844. https://doi.org/10.1038/s41598-020-71887-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Inflammatory Mediators in Glioma Microenvironment Play a Dual Role in Gliomagenesis and Mesenchymal Stem Cell Homing: Implication for Cellular Therapy

Investigators highlight the bidirectional communication of glioma cells and tumor-associated immune cells, the inflammatory mediators enabling leukocytes and transplantable MSC migration, and review preclinical and human clinical trials using MSCs as delivery vehicles.
[Mayo Clinic Proceedings]
Full Article
Bookmark

No account yet? Register

0
Share

Winnipeg Foundation Innovation Fund Awards Diverse Rady Faculty Projects

Two interdisciplinary research teams at the University of Manitoba’s Rady Faculty of Health Sciences have received one-year grants from The Winnipeg Foundation Innovation Fund for cutting-edge projects that will advance research in the areas of brain disease and mother-infant health.
[University of Manitoba]
Press Release
Bookmark

No account yet? Register

0
Share
Share